Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer
- PMID: 27753009
- DOI: 10.1007/978-3-319-42044-8_1
Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer
Abstract
In the present study, we investigated whether circulating cell-free microRNAs serve as potential biomarkers in epithelial ovarian cancer (EOC) patients. Circulating miR-373, miR-200a, miR-200b and miR-200c were quantified in a cohort of 60 EOC patients, 20 patients with benign ovarian diseases and 32 healthy women using quantitative TaqMan MicroRNA assays. The serum concentrations of cell-free miR-373, miR-200a, miR-200b and miR-200c were significantly higher in EOC patients than in healthy women (p = 0.0001). With a sensitivity of 83 % and a specificity of 100 %, the combination of miR-200a, miR-200b and miR-200c could differ between malignant and benign ovarian tumors (p = 0.0001). Elevated levels of these cell-free microRNAs could be detected in FIGO I-II and FIGO III-IV stages, grading G1-2 and G3 and lymph node-negative and -positive EOC. In conclusion, the increased serum levels of this microRNA panel have diagnostic value for distinguishing healthy controls and benign tumors from EOC.
Keywords: Cell-free miRNAs; FIGO stage; Metastases; Tumor progression.
Similar articles
-
Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.Oncotarget. 2016 Mar 29;7(13):16923-35. doi: 10.18632/oncotarget.7850. Oncotarget. 2016. PMID: 26943577 Free PMC article.
-
Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.Clin Transl Oncol. 2015 Oct;17(10):779-87. doi: 10.1007/s12094-015-1303-1. Epub 2015 Jun 11. Clin Transl Oncol. 2015. PMID: 26063644
-
Serum microRNA-92 expression in patients with ovarian epithelial carcinoma.J Int Med Res. 2013 Oct;41(5):1456-61. doi: 10.1177/0300060513487652. Epub 2013 Aug 20. J Int Med Res. 2013. PMID: 23963852
-
miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.Oncotarget. 2016 Dec 6;7(49):81621-81633. doi: 10.18632/oncotarget.13154. Oncotarget. 2016. PMID: 27835595 Free PMC article. Review.
-
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer.Int J Mol Sci. 2015 Jul 24;16(8):16833-47. doi: 10.3390/ijms160816833. Int J Mol Sci. 2015. PMID: 26213923 Free PMC article. Review.
Cited by
-
Effects of miR-373 Inhibition on Glioblastoma Growth by Reducing Limk1 In Vitro.J Immunol Res. 2020 Sep 28;2020:7671502. doi: 10.1155/2020/7671502. eCollection 2020. J Immunol Res. 2020. PMID: 33062725 Free PMC article.
-
imPlatelet classifier: image-converted RNA biomarker profiles enable blood-based cancer diagnostics.Mol Oncol. 2021 Oct;15(10):2688-2701. doi: 10.1002/1878-0261.13014. Epub 2021 Jun 20. Mol Oncol. 2021. PMID: 34013585 Free PMC article.
-
Diagnosis accuracy of the miR-200 family tumor marker series in ovarian cancer: a systematic review and meta-analysis.Transl Cancer Res. 2022 Jul;11(7):2283-2290. doi: 10.21037/tcr-22-864. Transl Cancer Res. 2022. PMID: 35966325 Free PMC article.
-
Inhibition of miR-214-3p Aids in Preventing Epithelial Ovarian Cancer Malignancy by Increasing the Expression of LHX6.Cancers (Basel). 2019 Dec 2;11(12):1917. doi: 10.3390/cancers11121917. Cancers (Basel). 2019. PMID: 31810245 Free PMC article.
-
The current trend of exosome in epithelial ovarian cancer studies: A bibliometric review.Front Pharmacol. 2023 Mar 9;14:1082066. doi: 10.3389/fphar.2023.1082066. eCollection 2023. Front Pharmacol. 2023. PMID: 36969852 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical